Vincristine-Induced Neuropathy in Patients Diagnosed with Solid and Hematological Malignancies: The Role of Dose Rounding.
cancer
dose rounding
hematologic malignancies
neuropathy
solid tumors
vincristine
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
received:
19
07
2023
revised:
22
08
2023
accepted:
30
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-induced neuropathy is a challenging adverse effect that impacts quality of life and treatment course. The dose rounding of chemotherapies is a strategy that is commonly used in clinical practice. Nevertheless, the frequency of developed neuropathy in vincristine first-time users and the potential association with dose rounding remains elusive. A retrospective analysis was conducted on patients administered vincristine for the first time between 2016 and 2022 using the King Saud University Medical City (KSUMC) database. Patients were stratified into pediatric and adult groups. Neuropathy frequency, its association with demographic and clinical parameters, and the Impact of dose rounding were assessed using SPSS software version 28. Approximately 34.6% of patients were diagnosed with neuropathy after vincristine administration. Autonomic neuropathy was common among affected adults and pediatric patients (55.1% and 56.1%, respectively), while cranial neuropathy was more frequent in pediatric patients. Higher BSA ( Our findings demonstrate that autonomic neuropathy is the most common vincristine-related neuropathy, regardless of the patient's age. Dose rounding is a significant determinant of vincristine-induced neuropathy in both groups. Further studies are needed to evaluate the variables that exacerbate or prevent neuropathy associated with the first-time use of vincristine.
Sections du résumé
BACKGROUND
BACKGROUND
Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-induced neuropathy is a challenging adverse effect that impacts quality of life and treatment course. The dose rounding of chemotherapies is a strategy that is commonly used in clinical practice. Nevertheless, the frequency of developed neuropathy in vincristine first-time users and the potential association with dose rounding remains elusive.
METHODS
METHODS
A retrospective analysis was conducted on patients administered vincristine for the first time between 2016 and 2022 using the King Saud University Medical City (KSUMC) database. Patients were stratified into pediatric and adult groups. Neuropathy frequency, its association with demographic and clinical parameters, and the Impact of dose rounding were assessed using SPSS software version 28.
RESULTS
RESULTS
Approximately 34.6% of patients were diagnosed with neuropathy after vincristine administration. Autonomic neuropathy was common among affected adults and pediatric patients (55.1% and 56.1%, respectively), while cranial neuropathy was more frequent in pediatric patients. Higher BSA (
CONCLUSIONS
CONCLUSIONS
Our findings demonstrate that autonomic neuropathy is the most common vincristine-related neuropathy, regardless of the patient's age. Dose rounding is a significant determinant of vincristine-induced neuropathy in both groups. Further studies are needed to evaluate the variables that exacerbate or prevent neuropathy associated with the first-time use of vincristine.
Identifiants
pubmed: 37685729
pii: jcm12175662
doi: 10.3390/jcm12175662
pmc: PMC10488791
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Paediatr Neurol. 2000;4(5):225-33
pubmed: 11030069
Indian J Pediatr. 2010 Jan;77(1):97-100
pubmed: 19936661
J Child Neurol. 2014 Jul;29(7):932-7
pubmed: 23781018
Cancer Treat Rev. 1994 Apr;20(2):191-214
pubmed: 8156541
J Oncol Pharm Pract. 2010 Dec;16(4):251-5
pubmed: 19965948
Front Mol Neurosci. 2017 May 31;10:174
pubmed: 28620280
Crit Rev Oncol Hematol. 2017 Jun;114:114-130
pubmed: 28477739
Soins. 1989 Dec;(531):49-50
pubmed: 2485978
J Oncol Pract. 2018 Mar;14(3):e130-e136
pubmed: 29400987
Mycoses. 2012 Jul;55(4):290-7
pubmed: 22126626
Front Mol Biosci. 2022 Oct 14;9:1015746
pubmed: 36310587
JCO Clin Cancer Inform. 2021 Aug;5:805-810
pubmed: 34351786
J Med Invest. 2021;68(3.4):232-237
pubmed: 34759136
J Antimicrob Chemother. 2011 Sep;66(9):2136-9
pubmed: 21685202
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
Ann Oncol. 2000 Jan;11(1):69-72
pubmed: 10690390
Med Toxicol. 1986 Nov-Dec;1(6):421-7
pubmed: 3540519
Support Care Cancer. 2004 Sep;12(9):653-6
pubmed: 14986078
Support Care Cancer. 2011 Dec;19(12):1991-6
pubmed: 21080201
Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87
pubmed: 10226730
J Clin Oncol. 2014 Nov 1;32(31):3463-9
pubmed: 25185093
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28544423
Clin Transl Oncol. 2010 Feb;12(2):81-91
pubmed: 20156778
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28623857
J Clin Med Res. 2014 Aug;6(4):252-60
pubmed: 24883150
Nutrients. 2017 May 25;9(6):
pubmed: 28587059
J Oncol Pharm Pract. 2018 Oct;24(7):507-510
pubmed: 28732452
Cancer Chemother Pharmacol. 2019 Sep;84(3):471-485
pubmed: 31214762
J Oncol Pharm Pract. 2017 Jul;23(5):379-383
pubmed: 27000279
Genes Dis. 2022 Mar 18;10(4):1367-1401
pubmed: 37397557
J Antimicrob Chemother. 2011 Aug;66(8):1853-6
pubmed: 21652620
J Peripher Nerv Syst. 2009 Sep;14(3):184-9
pubmed: 19909482
J Pharmacol Exp Ther. 2007 May;321(2):553-63
pubmed: 17272675
Cancer Cell Int. 2022 Jun 2;22(1):206
pubmed: 35655306
Ann Intern Med. 1974 Jun;80(6):733-7
pubmed: 4364934
Drugs. 1992;44 Suppl 4:1-16; discussion 66-9
pubmed: 1283846